The U.S. Food and Drug Administration (FDA) has accepted and given priority review to AstraZeneca‘s application requesting a new dosing regimen for Imfinzi (durvalumab) to treat certain non-small cell lung cancer (NSCLC) and bladder cancer patients. If approved, Imfinzi could be administered at a fixed dose of 1,500 mg every four weeks, an alternative to the weight-based dosing of 10 mg/kg every two weeks now set for these two indications. A similar once monthly, fixed dose regimen is approved for…
You must be logged in to read/download the full post.
The post Imfinzi as Once Monthly NSCLC, Bladder Cancer Treatment Under FDA Review appeared first on BioNewsFeeds.